10 Best Research Peptides in 2026

BPC-157 (Body Protection Compound-157) remains the single most-studied peptide in preclinical research. Derived from a protein in human gastric juice, this 15-amino-acid sequence has been investigated in over 120 published papers — primarily from Professor Predrag Sikiric's group at the University of Zagreb. Studies have explored its interactions with the FAK-paxillin pathway, the nitric oxide system, VEGF expression, and neurotransmitter systems ^[1]. The caveat: all data is preclinical. No completed human trials exist, but its sheer volume of consistent results across diverse injury models makes it the most data-rich peptide in this category.

Tirzepatide is in a different league — it has completed Phase 3 clinical trials (SURPASS and SURMOUNT programs) and received FDA approval as Mounjaro® and Zepbound® for specific indications. As a dual GIP/GLP-1 receptor agonist, it represents a paradigm shift in metabolic peptide research. The research-grade compound remains one of the most requested for in-vitro receptor binding studies and metabolic pathway assays ^[2]. Its dual-agonist mechanism has opened entirely new questions about incretin signaling that researchers are actively exploring.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is notable for being one of the few peptides with both in-vitro and limited human data. Naturally occurring in human plasma, its concentration declines with age — from ~200 ng/mL at age 20 to ~80 ng/mL by age 60. Studies have investigated its effects on metalloproteinase regulation, collagen synthesis, and extracellular matrix remodeling ^[3]. The copper binding gives it unique redox chemistry that distinguishes it from other research peptides.

NAD+ (nicotinamide adenine dinucleotide) isn't technically a peptide — it's a coenzyme — but it's become a cornerstone of longevity research. Present in every living cell, it's essential for over 500 enzymatic reactions. The explosion of sirtuin research (SIRT1-SIRT7) in the last decade has made NAD+ one of the most actively studied molecules in aging biology ^[4]. Research-grade NAD+ is widely used in cell-free enzymatic assays and mitochondrial function studies. The open question: does exogenous NAD+ supplementation meaningfully affect intracellular levels?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. It has FDA approval as Egrifta® for a specific indication (HIV-associated lipodystrophy), giving it rare clinical validation in the secretagogue category. In research contexts, it's studied for its clean GH-axis activation without directly binding the GH receptor — a mechanistic distinction from exogenous GH ^[5]. It's increasingly popular in in-vitro assays exploring pulsatile GH release patterns.

Retatrutide is the next evolution beyond tirzepatide — a tri-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data (published in NEJM, 2023) showed unprecedented results in metabolic endpoint studies ^[6]. For researchers, it represents the cutting edge of multi-receptor agonism. The triple mechanism raises fundamental questions about how these three receptor systems interact, making it one of the most scientifically interesting compounds in metabolic research right now.

TB-500 is the active fragment of thymosin beta-4, a 43-amino-acid protein that regulates actin polymerization — the fundamental process by which cells move, divide, and maintain structure. Studies have focused on its role in cell migration assays and angiogenesis models ^[7]. It's often studied alongside BPC-157 in combination models, though the two have completely different mechanisms. TB-500's actin-binding properties make it uniquely valuable for cytoskeletal research.

MOTS-c is a mitochondrial-derived peptide (MDP) — encoded in mitochondrial DNA rather than nuclear DNA. Discovered in 2015 by Dr. Changhan Lee's lab at USC, it's one of the most recently identified signaling peptides. Studies show it activates AMPK (the cell's energy sensor) and translocates to the nucleus during metabolic stress ^[8]. It represents an entirely new class of retrograde signaling molecules that challenge our understanding of how mitochondria communicate with the rest of the cell.

Semax is a synthetic heptapeptide — a modified fragment of ACTH (adrenocorticotropic hormone) with a Pro-Gly-Pro extension that prevents enzymatic degradation. Developed at the Institute of Molecular Genetics (Russian Academy of Sciences), it has over 200 published studies — mostly in Russian-language journals, which limits its visibility in Western research databases ^[9]. Studies have investigated its effects on BDNF expression, neurotrophic factor modulation, and neuroprotective signaling in cell culture models.

CJC-1295 (a modified GHRH analogue) and ipamorelin (a selective ghrelin mimetic) are studied individually and in combination for their complementary GH-axis mechanisms. CJC-1295 acts on GHRH receptors while ipamorelin targets ghrelin receptors — two distinct pathways that converge on pituitary somatotroph cells ^[10]. The combination is frequently used in in-vitro receptor co-activation studies exploring synergistic GH release patterns. Neither compound has completed Phase 3 trials.